LSE:AZNPharmaceuticals
AstraZeneca’s Oncology And Respiratory Advances Meet Undervalued Share Price
FDA approval granted for a new CALQUENCE combination therapy in chronic lymphocytic leukemia.
Positive Phase III results reported for BREZTRI in patients with uncontrolled asthma.
EMA validates a filing for ENHERTU in HER2 positive breast cancer.
AstraZeneca, LSE:AZN, is adding fresh clinical and regulatory progress to a share price that stands at £151.1. The stock has returned 11.2% year to date and 27.9% over the past year, with a 47.7% return over three years and 144.9% over five years...